Haleon plc Files Director/PDMR Shareholding Report
Ticker: HLNCF · Form: 6-K · Filed: Dec 19, 2024 · CIK: 1900304
Sentiment: neutral
Topics: insider-filing, disclosure
TL;DR
Haleon plc filed a 6-K on Dec 19, 2024, detailing director shareholdings.
AI Summary
On December 19, 2024, Haleon plc filed a Form 6-K to report a Director/PDMR Shareholding. This filing details share transactions by individuals who are directors or Persons Discharging Managerial Responsibility within the company.
Why It Matters
This filing provides transparency into the stock ownership of key company insiders, which can offer insights into their confidence in the company's performance.
Risk Assessment
Risk Level: low — This is a routine disclosure of director shareholdings and does not indicate any new material risks for the company.
Key Players & Entities
- Haleon plc (company) — Registrant
- DRVW 2022 Ltd (company) — Former company name
- 19 December 2024 (date) — Filing date
FAQ
What type of report is Haleon plc filing?
Haleon plc is filing a Form 6-K, which is a Report of Foreign Private Issuer.
What is the specific exhibit attached to this Form 6-K?
The specific exhibit is titled 'Director/PDMR Shareholding' and is designated as Exhibit 99.1.
When was this Form 6-K filed?
This Form 6-K was filed on December 19, 2024.
What was Haleon plc's former name?
Haleon plc's former name was DRVW 2022 Ltd.
What is the primary purpose of a Form 6-K filing?
A Form 6-K is used by foreign private issuers to report information that they have made or are required to make public in their home country, or that they have distributed or are required to distribute to their security holders.
Filing Stats: 546 words · 2 min read · ~2 pages · Grade level 18.8 · Accepted 2024-12-19 12:58:15
Filing Documents
- a8158q.htm (6-K) — 42KB
- a8158q000.jpg (GRAPHIC) — 3KB
- 0001654954-24-015738.txt ( ) — 48KB
From the Filing
SHAREHOLDING a8158q UNITED STATES   SECURITIES AND EXCHANGE COMMISSION   Washington, D.C. 20549     FORM 6-K   REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934   For the month of December 2024   Commission File Number: 001-41411   Haleon plc (Translation of registrant’s name into English)   Building 5, First Floor, The Heights, Weybridge, Surrey, KT13 0NY (Address of principal executive offices)     Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:     Form 20-F ☒   Form 40-F ☐       EXHIBIT INDEX   Exhibit Number Description 99.1  19 December 2024 - “Director/PDMR Shareholding” 99.1     ​ Haleon plc :  Director/PDMR Shareholding   ​   19 December 2024 :   Haleon plc (the "Company" or "Haleon") (LSE/NYSE:HLN) today announces notification and public disclosure in accordance with the requirements of The UK Market Abuse Regulation of Transactions by Persons Discharging Managerial Responsibilities ("PDMRs").   1      Details of the person discharging managerial responsibilities / person closely associated      a)     Name     Adrian Morris 2      Reason for the notification      a)     Position/status     General Counsel - PDMR b)     Initial notification /Amendment     Initial Notification  3      Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor      a)     Name     Haleon plc  b)     LEI     549300PSB3WWEODCUP19  4      Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted      a)     Description of the financial instrument, type of instrument   Ordinary Shares of £0.01 each     Identification code   GB00BMX86B70   b)     Nature of the transaction     Grant of a 3-year option over Ordinary Shares under the 2024 Haleon Share Save Plan which will first become exercisable 1 February 2028.   c)     Price(s) and volume(s)               Price(s)  Volume(s)        £3.00 6,150             d)     Aggregated information         - Aggregated volume        - Price        e)     Date of the transaction     19 December 2024 f)     Place of the transaction     Outside a trading venue   Amanda Mellor Company Secretary   About Haleon Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans five major categories - Oral Health, Pain Relief, Respiratory Health, Digestive Health and Other, and Vitamins, Minerals and Supplements (VMS). Its long-standing brands - such as Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, parodontax and Centrum - are built on trusted science, innovation and deep human understanding.   For more information, please visit  www.haleon.com .    SIGNATURE       Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.       HALEON PLC (Registrant)   Date: December 19, 2024 By: /s/ Amanda Mellor     Name: Amanda Mellor     Title: Company Secretary